Our latest articles
Zantac burns big pharma
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Pfizer bets $5.4bn against gene therapies in sickle cell
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
US drug pricing reform happens at last
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
Karuna bucks the neuro trend
The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.
World Lung – Toxicity scuppers Amgen’s first-line lung hopes
In the Kras plus checkpoint inhibitor race it looks like advantage Mirati, for now.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Amgen picks its moment to strike for Chemocentryx
The $3.7bn price is cheaper than it would have been last year, but Tavneos must still fulfill its pipeline-in-a-product potential.
